Enovis (NYSE:ENOV) Shares Up 14.1% – Should You Buy?

Shares of Enovis Corporation (NYSE:ENOV) were up 14.1% during trading on Wednesday. The stock traded as high as $24.01 and last traded at $23.8440. 205,270 shares changed hands during trading, a decline of 83% from the average daily volume of 1,233,179 shares. The stock had previously closed at $20.89.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Weiss Ratings raised Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. Citizens Jmp reduced their target price on shares of Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a research note on Wednesday, September 2nd. Needham & Company LLC decreased their target price on shares of Enovis from $52.00 to $34.00 and set a “buy” rating for the company in a research report on Monday, October 12th. Wells Fargo & Company dropped their price target on shares of Enovis from $39.00 to $33.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 2nd. Finally, BTIG Research reduced their price objective on shares of Enovis from $40.00 to $36.00 and set a “buy” rating for the company in a research note on Tuesday, September 1st. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Enovis presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.25.

Enovis Stock Up 16.9%

The business has a fifty day simple moving average of $19.82 and a two-hundred day simple moving average of $23.05. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of -1.26 and a beta of 1.31. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.90 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.05. The firm had revenue of $582.78 million for the quarter, compared to analyst estimates of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%. The business’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same period last year, the company earned $0.79 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities analysts expect that Enovis Corporation will post 3.15 EPS for the current year.

Insider Activity

In other Enovis news, CEO Damien Mcdonald bought 13,035 shares of the business’s stock in a transaction on Friday, September 4th. The stock was purchased at an average cost of $19.15 per share, for a total transaction of $249,620.25. Following the completion of the purchase, the chief executive officer directly owned 247,077 shares of the company’s stock, valued at approximately $4,731,524.55. This trade represents a 5.57% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Oliver Engert purchased 5,140 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The shares were bought at an average cost of $19.46 per share, for a total transaction of $100,024.40. Following the completion of the acquisition, the insider directly owned 61,238 shares in the company, valued at $1,191,691.48. The trade was a 9.16% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders acquired 23,293 shares of company stock worth $449,599. Insiders own 2.90% of the company’s stock.

Institutional Trading of Enovis

Large investors have recently bought and sold shares of the business. Private Management Group Inc. lifted its position in Enovis by 31.3% in the 3rd quarter. Private Management Group Inc. now owns 1,792,429 shares of the company’s stock worth $32,748,000 after buying an additional 427,347 shares during the last quarter. Paradigm Capital Management Inc. NY raised its stake in shares of Enovis by 70.2% during the first quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock worth $40,420,000 after acquiring an additional 732,917 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Enovis by 38.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company’s stock worth $24,430,000 after acquiring an additional 287,687 shares during the last quarter. Front Street Capital Management Inc. grew its holdings in shares of Enovis by 106.1% during the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock valued at $16,973,000 after purchasing an additional 384,124 shares during the last quarter. Finally, Quantinno Capital Management LP grew its holdings in shares of Enovis by 130.8% during the 1st quarter. Quantinno Capital Management LP now owns 604,500 shares of the company’s stock valued at $13,752,000 after purchasing an additional 342,556 shares during the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

About Enovis

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.